The cerebrovascular risks associated with tamoxifen use

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 501-507

  Bushnell, Cheryl ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cerebral venous thrombosis; Risk factors; Stroke; Tamoxifen

Indexed keywords

ANASTROZOLE; RALOXIFENE; TAMOXIFEN;

ARTERY THROMBOSIS; BREAST CANCER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; ENDOMETRIUM CANCER; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; PARADOXICAL EMBOLISM; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ATHEROSCLEROSIS; BREAST NEOPLASMS; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; RISK FACTORS; TAMOXIFEN;

EID: 19444365784     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.501     Document Type: Review

References (43)

1. FISHER B, DIGNAM JJ, WOLMARK N et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 353:1993-2000.
2. FISHER B, BRYANT J, DIGNAM JJ et al.: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. (2002) 20:4141-4149.
3. CUZICK J, POWLES T, VERONESI U et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 361:296-300.
4. FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90:1371-1388.
5. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet (2002) 360:817-824.
6. CHANG J, POWLES T, ASHLEY S et al.: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann. Oncol. (1996) 7:671-675.
7. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialisits' Group: Anastrazole alone or in combination with tamoxifen versus tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet (2002) 359:2131-2139.
8. CUSHMAN M, COSTANTINO JP, TRACY RP et al.: Tamoxifen and cardiac risk factors in healthy women. Suggestion of an anti-inflammatory effect. Arteriocler. Thromb. Vasc. Biol. (2001) 21:255-261.
9. MCDONALD CC, ALEXANDER FE, WHYTE BW, FORREST AP, STEWART HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br. Med. J. (1995) 311:977-980.
10. VERONESI U, MAISONNEUVE P, SACCHINI V, ROTMENSZ N, BOYLE P: Tamoxifen for breast cancer among hysterectomised women. Lancet (2002) 359:1122-1124.
11. HOLLI K, VALAVAARA R, BLANCO G et al.: Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. (2000) 18:3487-3494.
12. AKDAL G, DONMEZ B, CAKMAKCI H, GULMEN YENER G: A case with cerebral thrombosis receiving tamoxifen treatment. European J. Neurol. (2001) 8:723-724.
13. MASJUAN J, PARDO J, CALLEJO J, ANDRES M, ALVAREZ-CERMENO J: Tamoxifen: A new risk factor for cerebral sinus thrombosis. Neurology (2004) 62:334-335.
14. BOUSSER M-G, BARNETT HJ: Cerebral Venous Thrombosis. In: Barnett HJ, Mohr J, Stein BM, Yatsu FM, Eds. Stroke. Pathophysiology, Diagnosis, and Management (3rd Ed). New York: Churchill Livingstone. (1998) pp623-647.
15. PEMBERTON K, MELISSARI E, KAKKAR V: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul. Fibrinolysis (1993) 4:935-942.
16. MAMBY CC, LOVE RR, FEYZI J: Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Cancer Res. Treat. (1994) 30:311-314.
17. CUSHMAN M, COSTANTINO JP, BOVILL EG et al.: Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br. J. Haematol. (2003) 120:109-116.
18. MANNUCCI P, BETTEGA D, CHANTARANGKUL V et al.: Effect of tamoxifen on measurements of hemostasis in healthy women. Arch. Intern. Med. (1996) 156:1806-1810.
19. LOWE G, WOODWARD M, VESSEY M et al.: Thrombotic variables an drisk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb. Haemost. (2000) 83:530-535.
20. WEITZ IC, ISRAEL VK, LIEBMAN HA: Tamoxifen-associated venous thrombosis and activated protein C resistance due to Factor V Leiden. Cancer (1997) 79:2024-2027.
21. BRAITHWAITE R, CHLEBOWSKI RT, Lau J et al.: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. (2003) 18:937-947.
22. BUSHNELL CD, GOLDSTEIN LB: Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis. Neurology (2004) 63:1230-1233.
23. VERONESI U, MAISONNEUVE P, COSTA A et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian ramdomised trial among hysterecromised women. Lancet (1998) 352:93-97.
24. POWLES T, EELES R, ASHLEY S et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 352:98-101.
25. DIGNAM JJ, FISHER B: Occurrence of stroke with tamoxifen in NSABP-B-24. Lancet (2000) 355:848-849.
26. PETTITI DB: Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. In: Methods for Quantitative Synthesis in Medicine (2nd Ed). New York: Oxford University Press, 2000.
27. GEIGER AM, FISCHBERG GM, CHEN W, BERNSTEIN L: Stroke risk and tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. (2004) 96:1528-1536.
28. BONANNI B, JOHANSSON H, GANDINI S et al.: Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. J. Thromb. Haemost. (2003) 1:2149-2152.
29. GREY AB, STAPLETON JP, EVANS MC, REID IR: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J. Clin. Endocrin. Metab. (1995) 80:3191-3195.
30. PENOTTI M, SIRONI L, MIGLIERINA L et al.: The effect of tamoxifen and transdermal 17 beta-estradiol on cerebral arterial vessles: A randomized controlled study. Am. J. Obstet. Gynecol. (1998) 178:801-805.
31. ONG PJ, LINARDOU H, GRAHAM HA et al.: Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am. Heart J. (2001) 142:e6.
32. CLARKE SC, SCHOFIELD PM, GRACE AA, METCALFE JC, KIRSCHENLOHR HL: Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation (2001) 103:1497-1502.
33. SIMON T, BOUTOUYRIE P, SIMON J et al.: Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation (2002) 106:2952-2929
34. KINSINGER LS, HARRIS R, WOOLF SH, SOX HC, LOHR KN: Chemoprevention of breast cancer: A summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 137:E59-E69.
35. CHANT H, MCCOLLUM C: Stroke in young adults: The role of paradoxical embolism. Thromb. Haemost. (2001) 85:22-29.
36. RANOUX D, COHEN A, CABANES L et al.: Patent foramen ovale: Is stroke due to paradoxical embolism? Stroke (1993) 24:31-34.
37. CRAMER SC, RORDORF G, MAKI JH et al.: Increased Pelvic Vein Thrombi in Cryptogenic Stroke. Results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) Study. Stroke (2004) 35:46-50.
38. FINELLI PF, SCHAUER PK: Cerebral sinus thrombosis with tamoxifen. Neurology (2001) 56:1113.
39. KIMELBERG H, FEUSTEL P, Y J et al.: Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport (2000) 11:2675-2679.
40. MEHTA S, DHANDAPANI K, DE SEVILLA L et al.: Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology (2003) 77:44-50.
41. BONNETERRE J, BUZDAR A, NABHOLTZ J-MA et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer (2001) 92:2247-2258.
42. WOLF PA, D'AGOSTINO RB, BELANGER AJ, KANNEL WB: Probability of stroke: A risk profile from the Framingham study. Stroke (1991) 22:312-318.
43. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. (1991) 325:445-453.